🏛️ Verified NIH Record • Updated 2025-03-24
The Genetics of Pulmonary Fibrosis (NCT03478553)
Idiopathic Pulmonary Fibrosis, a Disease Initiated by Mucociliary Dysfunction
🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research Sponsor: University of Colorado, Denver
🩺 Plain-English Summary (8th-Grade Level)
This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
Who can join: Review the eligibility criteria below.
Location: University of Colorado Anschutz Medical Campus — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
- Blood draw (OTHER)
- Questionnaire (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Colorado Anschutz Medical Campus — Aurora, Colorado
📞 Contact the Study Coordinator
Phone: (303) 724-8569
Email: rachel.warren@cuanschutz.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Idiopathic Pulmonary Fibrosis (IPF)
- A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. — Birmingham, Alabama
- Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis — Denver, Colorado
- A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension — Norfolk, Virginia
- Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF) — Palm Spring, California
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis — Birmingham, Alabama
Explore by condition: All Idiopathic Pulmonary Fibrosis (IPF) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.